Array BioPharma Price Target Raised to $4.00 at BMO Capital Markets (ARRY)
BMO Capital Markets raised their price objective on shares of Array BioPharma (NASDAQ:ARRY) from $3.00 to $4.00 in a research note issued on Friday, Analyst Ratings News reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ target price would indicate a potential downside of 22.03% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Array BioPharma from $7.00 to $8.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $6.75.
Array BioPharma (NASDAQ:ARRY) opened at 5.13 on Friday. Array BioPharma has a 52-week low of $3.25 and a 52-week high of $7.10. The stock has a 50-day moving average of $5.85 and a 200-day moving average of $5.7. The company’s market cap is $600.3 million.
Array BioPharma (NASDAQ:ARRY) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. The company had revenue of $14.20 million for the quarter, compared to the consensus estimate of $11.20 million. During the same quarter last year, the company posted ($0.13) earnings per share. Array BioPharma’s revenue was down 10.1% compared to the same quarter last year. Analysts expect that Array BioPharma will post $-0.70 EPS for the current fiscal year.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.